209 results on '"Agustoni, Francesco"'
Search Results
2. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
3. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
4. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group
5. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era
6. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
7. Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center “Blue Sky Radiomics” study on stage III unresectable NSCLC
8. Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling
9. Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design.
10. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
11. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
12. Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach
13. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
14. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
15. Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease
16. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines
17. The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs
18. CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned
19. Smoking Habit and Respiratory Function Predict Patients’ Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage
20. Rationale and design of a single-arm, phase 2, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC: the DEDALUS trial.
21. Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
22. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
23. Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
24. Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results
25. Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
26. Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies
27. Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review
28. Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?
29. Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients
30. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
31. Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
32. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry
33. Additional file 1 of Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
34. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
35. Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
36. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
37. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach
38. Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study
39. The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
40. Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
41. The Clinical Value of Nutritional Care before and during Active Cancer Treatment
42. Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study
43. The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
44. Radiomics features as predictive and prognostic biomarkers in NSCLC
45. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
46. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
47. Integrating Data from Multidisciplinary Management of Malignant Pleural Mesothelioma: A Cohort Study
48. Multidisciplinary Approach in the Evaluation and Management of Patients with Malignant Pleural Mesothelioma. A Single Center Experience
49. Resilience in Cancer Care at the Time of COVID-19: Practical Approach to the Management of Cancer Patients During the COVID-19 Emergency in a Large Italian Community Hospital
50. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.